Stocks of Adaptive Biotechnologies Corp (NASDAQ:ADPT) traded higher last session on Wall Street, down -12.16% to $8.81.
ADPT stock price is now 12.38% away from the 50-day moving average and 42.18% away from the 200-day moving average. The market capitalization of the company currently stands at $1.34B.
With the price target maintained at $9, Goldman recently Upgraded its rating from Neutral to Buy for Adaptive Biotechnologies Corp (NASDAQ: ADPT). , while ‘Scotiabank’ rates the stock as ‘Sector Outperform’
In other news, ROBINS HARLAN S, Chief Scientific Officer sold 68,412 shares of the company’s stock on May 01 ’25. The stock was sold for $502,828 at an average price of $7.35. Upon completion of the transaction, the Chief Scientific Officer now directly owns 1,279,524 shares in the company, valued at $11.27 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 01 ’25, Officer Harlan Robins bought 68,412 shares of the business’s stock. A total of $503,512 was incurred on buying the stock at an average price of $7.36. A total of 4.61% of the company’s stock is owned by insiders.
During the past 12 months, Adaptive Biotechnologies Corp has had a low of $2.99 and a high of $10.28. As of last week, the company has a debt-to-equity ratio of 1.16, a current ratio of 2.92, and a quick ratio of 2.82.
The net profit margin was -74.84% and return on equity was -60.96% for ADPT. The company reported revenue of $52.44 million for the quarter, compared to $41.87 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 25.24 percent.
